Back to Search
Start Over
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.
- Source :
-
Oncology [Oncology] 2017; Vol. 93 (2), pp. 92-98. Date of Electronic Publication: 2017 Apr 28. - Publication Year :
- 2017
-
Abstract
- Objectives: There is little information on the risk factors for hepatocellular carcinoma (HCC) and outcome of treatment with an all-oral combination of direct-acting antiviral regimens following eradication of hepatitis C virus (HCV) RNA.<br />Methods: The study subjects were 1,170 patients with HCV genotype 1-related chronic liver disease treated with either NS5A inhibitor plus NS3/4A protease inhibitor (n = 707), NS5A inhibitor plus NS5B polymerase inhibitor (n = 345), or NS5A inhibitor, NS3/4A protease inhibitor plus ritonavir (n = 118), for 12-24 weeks. All patients were free of HCC before and during therapy.<br />Results: In this retrospective study, 22 patients developed HCC during the follow-up (time from the end of antiviral therapy until the last visit: 1.3 years). At 1 and 2 years after completion of the treatment, the cumulative HCC rates for the whole group were 1.8 and 2.3%, respectively, and 1.4 and 1.8%, respectively, for 1,065 patients who showed sustained virological response (SVR). The risk factors for HCC identified by multivariate analysis were hypoalbuminemia, thrombocytopenia, a high α-fetoprotein level, and non-SVR for all patients, and hypoalbuminemia and a high α-fetoprotein level for patients with SVR.<br />Conclusion: Eradication of HCV RNA by direct-acting antiviral regimens might reduce the risk of HCC. Albumin and α-fetoprotein levels are significant risk factors for HCC.<br /> (© 2017 S. Karger AG, Basel.)
- Subjects :
- Adult
Aged
Aged, 80 and over
Antiviral Agents administration & dosage
Carcinoma, Hepatocellular drug therapy
Carcinoma, Hepatocellular prevention & control
Female
Follow-Up Studies
Genotype
Hepacivirus genetics
Hepatitis C, Chronic complications
Hepatitis C, Chronic pathology
Humans
Immunotherapy, Adoptive
Liver Neoplasms drug therapy
Liver Neoplasms virology
Male
Middle Aged
Retrospective Studies
Risk Factors
Young Adult
Antiviral Agents adverse effects
Carcinoma, Hepatocellular pathology
Cell Transformation, Neoplastic drug effects
Hepacivirus drug effects
Hepatitis C, Chronic drug therapy
Liver Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1423-0232
- Volume :
- 93
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 28448999
- Full Text :
- https://doi.org/10.1159/000470910